Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Cheng Chih Hsu *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-3813-4373
Michelle Chamblee *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Chengjin Ye *Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.ORCID 0000-0002-1934-9494
Mohamed M Shamseldin *Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210.
Sung J Yoo *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-0892-2718
Pei Li *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Yuexiu Zhang *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Yajie LiuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Jesse M HallDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210.
Jiayu XuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-3948-1425
Hanson MiaoDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0009-0001-5980-4113
Ilada ThongpanCenter for Microbe and Immunity Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Mahesh K CCenter for Microbe and Immunity Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.ORCID 0000-0002-5177-9566
Xueya LiangDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Jacob S YountDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.
Mark E PeeplesCenter for Microbe and Immunity Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.ORCID 0000-0002-4582-317X
Prosper N BoyakaDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0001-6857-9088
Purnima DubeyDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-5454-8421
Luis Martinez-SobridoDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.ORCID 0000-0001-7084-0804
Shan-Lu LiuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-1620-3817
Jianrong LiDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-7130-1084
Funding
Role of the Non-canonical Inflammasome in SARS-CoV-2-mediated Pathology and CoagulopathyP01AI175399 · NIAID · OHIO STATE UNIVERSITY · PI Amal O Amer, Estelle A Cormet-Boyaka · 2024 to 2026
$12.0M
Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
Project 3: Dr. LiP01AI112524 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI PEEPLES, MARK E., RAMILO, OCTAVIO · 2015 to 2019
$6.8M
Mechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · PI Jacob Yount · 2017 to 2026
$4.3M
Messenger RNA Capping and Methylation in PneumovirusesR01AI090060 · NIAID · OHIO STATE UNIVERSITY · PI LI, JIANRONG · 2011 to 2023
$4.0M
Respiratory Syncytial Virus Targeting of the Human Airway EpitheliumR01AI093848 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI PEEPLES, MARK E. · 2012 to 2023
$3.8M
Host Responses to the Pore-Forming Toxin Listeriolysin OR01AI157205 · NIAID · OHIO STATE UNIVERSITY · PI AMER, AMAL O, BOYAKA, PROSPER N · 2021 to 2025
$3.2M
Targeting myeloid cells for regulation of alum-based immunityR01AI145144 · NIAID · OHIO STATE UNIVERSITY · PI BOYAKA, PROSPER N · 2020 to 2024
$3.1M
Mechanisms of lung and cardiac pathology in SARS-CoV-2 infectionsR01HL168501 · NHLBI · OHIO STATE UNIVERSITY · PI Amal O Amer, Jacob Yount · 2023 to 2026
$2.9M
Development of novel multivalent mucosal vaccines for human norovirusesR01AI183671 · NIAID · OHIO STATE UNIVERSITY · PI PURNIMA DUBEY, Siyuan Ding · 2025 to 2026
$1.6M
Interdisciplinary Program in Microbe-Host BiologyT32AI165391 · NIAID · OHIO STATE UNIVERSITY · PI RAJENDAR K DEORA, Daniel J Wozniak · 2022 to 2026
$1.5M
RNA epigenetic modifications in SARS-CoV-2R01AI185617 · NIAID · OHIO STATE UNIVERSITY · PI Jianrong Li, Mark E. Peeples · 2025 to 2026
$1.1M
CFF | Cystic Fibrosis Foundation Therapeutics (CFFT) 006781R223HHS | NIH | National Cancer Institute (NCI) U54CA260582HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1R01AI185617-01A1HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01AI175399HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI090060HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI093848HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI145144HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI157205HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI180667HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) T32AI165391HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI42733NCI NIH HHS U54 CA260582NHLBI NIH HHS R01 HL168501NIAID NIH HHS P01 AI112524NIAID NIH HHS P01 AI175399NIAID NIH HHS R01 AI090060NIAID NIH HHS R01 AI093848NIAID NIH HHS R01 AI130110NIAID NIH HHS R01 AI145144NIAID NIH HHS R01 AI157205NIAID NIH HHS R01 AI183671NIAID NIH HHS R01 AI185617NIAID NIH HHS R21 AI180667NIAID NIH HHS T32 AI165391
6 · The paper itself
Abstract
The emergence of immune-evasive SARS-CoV-2 Omicron subvariants highlights the need to develop a mucosal SARS-CoV-2 vaccine that can provide broad protection against virus infection and transmission. Here, we developed an intranasal monovalent SARS-CoV-2 vaccine expressing the six-proline-stabilized prefusion spike proteins (preS-6P) of Omicron XBB.1.5 based on the attenuated mumps virus (MuV) Jeryl Lynn (JL1) vaccine strain. We also developed an intranasal trivalent vaccine expressing the preS-6P of ancestral SARS-CoV-2 WA1 and two Omicron subvariants, BA.1 and XBB.1.5, using the attenuated measles virus (MeV) and MuV-JL1 and JL2 vaccine strains, respectively. Intranasal immunization of hamsters with the monovalent rMuV-JL1-XBB.1.5 or the trivalent vaccine induced high levels of neutralizing antibodies (NAbs) that efficiently neutralized Omicron subvariants XBB.1.5, EG.5, and JN.1, providing complete protection against these Omicron subvariants. Similar levels of Omicron XBB.1.5 NAbs were detected in monovalent rMuV-JL1-XBB.1.5 and trivalent vaccine groups even when hamsters had been preimmunized with the rMuV-JL2-WA1 vaccine, suggesting that both intranasal vaccines are effective in the presence of immune imprinting induced by the spike of SARS-CoV-2 WA1. Intranasal, but not subcutaneous, immunization generated high levels of S-specific mucosal IgA antibodies as well as lung-resident memory T cells in IFNAR1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission. · full record | OpenQuestion